Multidisciplinary Management of Costello Syndrome: Current Perspectives

References

• Costello JM. A new syndrome: mental subnormality and nasal papillomata. J Paediatr Child Health. 1977;13(2):114–118. doi:10.1111/j.1440-1754.1977.tb01135.x
   Google Scholar
• Gripp KW, Rauen KA Costello syndrome. 2020:1–29.
   Google Scholar
• Aoki Y, Niihori T, Kawame H, et al. Germline mutations in HRAS proto-oncogene cause Costello syndrome. Nat Genet. 2005;37(10):1038–1040. doi:10.1038/ng1641
   PubMed Web of Science ®Google Scholar
• Karnoub AE, Weinberg RA. Ras oncogenes: split personalities. Nat Rev Mol Cell Biol. 2008;9(7):517–531. doi:10.1038/nrm2438
   PubMed Web of Science ®Google Scholar
• Mitin N, Rossman KL, Der CJ. Signaling interplay in ras superfamily function. Curr Biol. 2005;15(14):563–574. doi:10.1016/j.cub.2005.07.010
   PubMed Web of Science ®Google Scholar
• Aoki Y, Niihori T, Inoue SI, Matsubara Y. Recent advances in RASopathies. J Hum Genet. 2016;61(1):33–39. doi:10.1038/jhg.2015.114
   PubMed Web of Science ®Google Scholar
• Tidyman WE, Rauen KA. Pathogenetics of the RASopathies. Hum Mol Genet. 2016;25(R2):R123–R132. doi:10.1093/hmg/ddw191
   PubMed Web of Science ®Google Scholar
• Motta M, Pannone L, Pantaleoni F, et al. Enhanced MAPK1 function causes a neurodevelopmental disorder within the RASopathy clinical spectrum. Am J Hum Genet. 2020;107(3):499–513. doi:10.1016/j.ajhg.2020.06.018
   PubMed Web of Science ®Google Scholar
• Tajan M, Paccoud R, Branka S, Edouard T, Yart A. The RASopathy family: consequences of germline activation of the RAS/MAPK pathway. Endocr Rev. 2018;39(5):676–700. doi:10.1210/er.2017-00232
   PubMed Web of Science ®Google Scholar
• Leoni C, Romeo DM, Pelliccioni M, et al. Musculo-skeletal phenotype of Costello syndrome and cardio-facio-cutaneous syndrome: insights on the functional assessment status. Orphanet J Rare Dis. 2021;16(1):1–11. doi:10.1186/s13023-021-01674-y
   PubMed Web of Science ®Google Scholar
• Kratz CP, Rapisuwon S, Reed H, Hasle H, Rosenberg PS. Cancer in Noonan, Costello, cardiofaciocutaneous and LEOPARD syndromes. Am J Med Genet C Semin Med Genet. 2011;157(2):83–89. doi:10.1002/ajmg.c.30300
   Web of Science ®Google Scholar
• Kratz CP, Franke L, Peters H, et al. Cancer spectrum and frequency among children with Noonan, Costello, and cardio-facio-cutaneous syndromes. Br J Cancer. 2015;112(8):1392–1397. doi:10.1038/bjc.2015.75
   PubMed Web of Science ®Google Scholar
• Estep AL, Tidyman WE, Teitell MA, Cotter PD, Rauen KA. HRAS mutations in Costello syndrome: detection of constitutional activating mutations in codon 12 and 13 and loss of wild-type allele in malignancy. Am J Med Genet A. 2006;140(1):8–16. doi:10.1002/ajmg.a.31078
   PubMed Web of Science ®Google Scholar
• Gripp KW, Lin AE, Stabley DL, et al. HRAS mutation analysis in Costello syndrome: genotype and phenotype correlation karen. Am J Hum Genet. 2006;221(3):212–221.
   Google Scholar
• Kerr B, Delrue M-A, Sigaudy S, et al. Genotype-phenotype correlation in Costello syndrome: HRAS mutation analysis in 43 cases. J Med Genet. 2006;43(5):401–405. doi:10.1136/jmg.2005.040352
   PubMed Web of Science ®Google Scholar
• Schulz AL, Albrecht B, Arici C, et al. Mutation and phenotypic spectrum in patients with cardio-facio-cutaneous and Costello syndrome. Clin Genet. 2008;73(1):62–70. doi:10.1111/j.1399-0004.2007.00931.x
   PubMed Web of Science ®Google Scholar
• Niihori T, Aoki Y, Okamoto N, et al. HRAS mutants identified in Costello syndrome patients can induce cellular senescence: possible implications for the pathogenesis of Costello syndrome. J Hum Genet. 2011;56(10):707–715. doi:10.1038/jhg.2011.85
   PubMed Web of Science ®Google Scholar
• Aoki Y, Niihori T, Narumi Y, Kure S, Matsubara Y. The RAS/MAPK syndromes: novel roles of the RAS pathway in human genetic disorders. Hum Mutat. 2008;29(8):992–1006. doi:10.1002/humu.20748
   PubMed Web of Science ®Google Scholar
• Lo IFM, Brewer C, Shannon N, et al. Severe neonatal manifestations of Costello syndrome. J Med Genet. 2008;45(3):167–171. doi:10.1136/jmg.2007.054411
   PubMed Web of Science ®Google Scholar
• Lorenz S, Petersen C, Kordaß U, Seidel H, Zenker M, Kutsche K. Two cases with severe lethal course of Costello syndrome associated with HRAS p.G12C and p.G12D. Eur J Med Genet. 2012;55(11):615–619. doi:10.1016/j.ejmg.2012.07.007
   PubMed Web of Science ®Google Scholar
• Weaver KN, Wang D, Cnota J, et al. Early-lethal Costello syndrome due to rare HRAS tandem base substitution (c.35-36GClAA; p.G12E)-associated pulmonary vascular disease. Pediatr Dev Pathol. 2014;17(6):421–430. doi:10.2350/14-05-1488-OA.1
   PubMed Web of Science ®Google Scholar
• Qian W, Zhang M, Huang H, et al. Costello syndrome with special cutaneous manifestations and HRAS G12D mutation: a case report and literature review. Mol Genet Genomic Med. 2021;9(6):e1690. doi:10.1002/mgg3.1690
   PubMed Web of Science ®Google Scholar
• Burkitt‐Wright EMM, Bradley L, Shorto J, et al. Neonatal lethal Costello syndrome and unusual dinucleotide deletion/insertion mutations in HRAS predicting p.Gly12Val. Am J Med Genet A. 2012;158A(5):1102–1110. doi:10.1002/ajmg.a.35296
   PubMed Web of Science ®Google Scholar
• Quélin C, Loget P, Rozel C, et al. Fetal Costello syndrome with neuromuscular spindles excess and p.Gly12Val HRAS mutation. Eur J Med Genet. 2017;60(7):395–398. doi:10.1016/j.ejmg.2017.03.014
   PubMed Web of Science ®Google Scholar
• Bend EG, Louie RJ, Stevenson RE. Fetal edema, not overgrowth, is associated with neonatal lethal Costello syndrome due to the HRAS p.Gly12Val mutation. Clin Dysmorphol. 2019;28(2):71–73. doi:10.1097/MCD.0000000000000260
   PubMed Web of Science ®Google Scholar
• Van Der Burgt I, Kupsky W, Stassou S, et al. Myopathy caused by HRAS germline mutations: implications for disturbed myogenic differentiation in the presence of constitutive HRas activation. J Med Genet. 2007;44(7):459–462. doi:10.1136/jmg.2007.049270
   PubMed Web of Science ®Google Scholar
• Gripp KW, Hopkins E, Sol-church K, et al. Phenotypic analysis of individuals with Costello syndrome due to HRAS p.G13C. Am J Med Genet A. 2011;155(4):706–716. doi:10.1002/ajmg.a.33884.Phenotypic
   Google Scholar
• Bertola D, Buscarilli M, Stabley DL, et al. Phenotypic spectrum of Costello syndrome individuals harboring the rare HRAS mutation p.Gly13Asp. Am J Med Genet A. 2017;173(5):1309–1318. doi:10.1002/ajmg.a.38178
   PubMed Web of Science ®Google Scholar
• Gripp KW, Morse LA, Axelrad M, et al. Costello syndrome: clinical phenotype, genotype, and management guidelines. Am J Med Genet A. 2019;179(9):1725–1744. doi:10.1002/ajmg.a.61270
   PubMed Web of Science ®Google Scholar
• Hiippala A, Vasilescu C, Tallila J, et al. The rare Costello variant HRAS c.173C>T (p.T58I) with severe neonatal hypertrophic cardiomyopathy. Am J Med Genet A. 2016;170(6):1433–1438. doi:10.1002/ajmg.a.37596
   PubMed Web of Science ®Google Scholar
• Gripp KW, Sol-Church K, Smpokou P, et al. An attenuated phenotype of Costello syndrome in three unrelated individuals with a HRAS c.179G>A (p.Gly60Asp) mutation correlates with uncommon functional consequences. Am J Med Genet A. 2015;167A(9):2085–2097. doi:10.1002/ajmg.a.37128
   PubMed Web of Science ®Google Scholar
• Denayer E, Parret A, Chmara M, et al. Mutation analysis in Costello syndrome: functional and structural characterization of the HRAS p.Lys117Arg mutation. Hum Mutat. 2008;29(2):232–239. doi:10.1002/humu.20616
   PubMed Web of Science ®Google Scholar
• Chiu ATG, Leung GK-C, Chu -YW-Y, Gripp KW, Chung BH-Y. A novel patient with an attenuated Costello syndrome phenotype due to an HRAS mutation affecting codon 146-Literature review and update. Am J Med Genet A. 2017;173(4):1109–1114. doi:10.1002/ajmg.a.38118
   PubMed Web of Science ®Google Scholar
• Gripp KW, Innes AM, Axelrad ME, et al. Costello syndrome associated with novel germline HRAS mutations: an attenuated phenotype? Am J Med Genet A. 2008;146A(6):683–690. doi:10.1002/ajmg.a.32227
   PubMed Web of Science ®Google Scholar
• Gripp KW, Kolbe V, Brandenstein LI, Rosenberger G. Attenuated phenotype of Costello syndrome and early death in a patient with an HRAS mutation (c.179G>T; p.Gly60Val) affecting signalling dynamics. Clin Genet. 2017;92(3):332–337. doi:10.1111/cge.12980
   PubMed Web of Science ®Google Scholar
• Sheffield BS, Yip S, Ruchelli ED, et al. Fatal congenital hypertrophic cardiomyopathy and a pancreatic nodule morphologically identical to focal lesion of congenital hyperinsulinism in an infant with Costello syndrome: case report and review of the literature. Pediatr Dev Pathol. 2015;18(3):237–244. doi:10.2350/14-07-1525-CR.1
   PubMed Web of Science ®Google Scholar
• Gripp KW, Hopkins E, Serrano A, Leonard NJ, Stabley DL, Sol-Church K. Transmission of the rare HRAS mutation (c. 173C > T; p.T58I) further illustrates its attenuated phenotype. Am J Med Genet A. 2012;158A(5):1095–1101. doi:10.1002/ajmg.a.35294
   PubMed Web of Science ®Google Scholar
• Girisha KM, Lewis LE, Phadke SR, Kutsche K. Costello syndrome with severe cutis laxa and mosaic HRAS G12S mutation. Am J Med Genet A. 2010;152A(11):2861–2864. doi:10.1002/ajmg.a.33687
   PubMed Web of Science ®Google Scholar
• Gripp KW, Stabley DL, Nicholson L, Hoffman JD, Sol-Church K. Somatic mosaicism for an HRAS mutation causes Costello syndrome. Am J Med Genet A. 2006;140(20):2163–2169. doi:10.1002/ajmg.a.31456
   PubMed Web of Science ®Google Scholar
• Liang J, Guo Y, Lu Z, Yu H, Wu L, Yao Z. Woolly hair nevus caused by somatic mutation and Costello syndrome caused by germline mutation in HRAS: consider parental mosaicism in prenatal counseling. J Dermatol. 2022;49(1):161–164. doi:10.1111/1346-8138.16177
   PubMed Web of Science ®Google Scholar
• Sol-Church K, Stabley DL, Demmer LA, et al. Male-to-male transmission of Costello syndrome: G12S HRAS germline mutation inherited from a father with somatic mosaicism. Am J Med Genet A. 2009;149A(3):315–321. doi:10.1002/ajmg.a.32639
   PubMed Web of Science ®Google Scholar
• Zampino G, Pantaleoni F, Carta C, et al. Diversity, parental germline origin, and phenotypic spectrum of de novo HRAS missense changes in Costello syndrome. Hum Mutat. 2007;28(3):265–272. doi:10.1002/humu.20431
   PubMed Web of Science ®Google Scholar
• Gripp KW, Bifeld E, Stabley DL, et al. A novel HRAS substitution (c.266C>G; p.S89C) resulting in decreased downstream signaling suggests a new dimension of RAS pathway dysregulation in human development. Am J Med Genet A. 2012;158A(9):2106–2118. doi:10.1002/ajmg.a.35449
   PubMed Web of Science ®Google Scholar
• Gremer L, De Luca A, Merbitz-Zahradnik T, et al. Duplication of Glu37 in the switch I region of HRAS impairs effector/GAP binding and underlies Costello syndrome by promoting enhanced growth factor-dependent MAPK and AKT activation. Hum Mol Genet. 2010;19(5):790–802. doi:10.1093/hmg/ddp548
   PubMed Web of Science ®Google Scholar
• Gripp KW, Baker L, Robbins KM, et al. The novel duplication HRAS c.186_206dup p. (Glu62_Arg68dup): clinical and functional aspects. Eur J Hum Genet. 2020;28(11):1548–1554. doi:10.1038/s41431-020-0662-4
   PubMed Web of Science ®Google Scholar
• Lorenz S, Lissewski C, Simsek-Kiper PO, et al. Functional analysis of a duplication (p.E63_D69dup) in the switch II region of HRAS: new aspects of the molecular pathogenesis underlying Costello syndrome. Hum Mol Genet. 2013;22(8):1643–1653. doi:10.1093/hmg/ddt014
   PubMed Web of Science ®Google Scholar
• Nagai K, Niihori T, Okamoto N, et al. Duplications in the G3 domain or switch II region in HRAS identified in patients with Costello syndrome. Hum Mutat. 2022;43(1):3–15. doi:10.1002/humu.24287
   PubMed Web of Science ®Google Scholar
• Xu F, Wang HJ, Lin ZM, Yu B. Recurrent duplication mutation in HRAS causing mild Costello syndrome in a Chinese patient. Clin Exp Dermatol. 2015;40(4):404–407. doi:10.1111/ced.12571
   PubMed Web of Science ®Google Scholar
• Pantaleoni F, Lev D, Cirstea IC, et al. Aberrant HRAS transcript processing underlies a distinctive phenotype within the RASopathy clinical spectrum. Hum Mutat. 2017;38(7):798–804. doi:10.1002/humu.23224
   PubMed Web of Science ®Google Scholar
• Schøler Nørgaard M, Mogra R, Pinner J, et al. Fetal Costello syndrome: description of phenotype of HRAS exon 1 mutations. Ultrasound Obstet Gynecol. 2020;55(2):274–275. doi:10.1002/uog.20281
   PubMed Web of Science ®Google Scholar
• Lin AE, O’Brien B, Demmer LA, et al. Prenatal features of Costello syndrome: ultrasonographic findings and atrial tachycardia. Prenat Diagn. 2009;29(7):682–690. doi:10.1002/pd.2276
   PubMed Web of Science ®Google Scholar
• Lan L-B, Li D-Z. Idiopathic polyhydramnios and foetal macrosomia in the absence of maternal diabetes: clinical vigilance for Costello syndrome. J Obstet Gynaecol. 2021;1–3. doi:10.1080/01443615.2021.1959533
   Google Scholar
• Shankar SP, Fallurin R, Watson T, et al. Ophthalmic manifestations in Costello syndrome caused by Ras pathway dysregulation during development. Ophthalmic Genet. 2021:1–10. DOI:10.1080/13816810.2021.1978103.
   Web of Science ®Google Scholar
• Zampino G, Mastroiacovo P, Ricci R, et al. Costello syndrome: further clinical delineation, natural history, genetic definition, and nosology. Am J Med Genet. 1993;47(2):176–183. doi:10.1002/ajmg.1320470210
   PubMed Web of Science ®Google Scholar
• Sammon MR, Doyle D, Hopkins E, et al. Normative growth charts for individuals with Costello syndrome. Am J Med Genet Part A. 2012;158 A(11):2692–2699. doi:10.1002/ajmg.a.35534
   Web of Science ®Google Scholar
• Leoni C, Onesimo R, Giorgio V, et al. Understanding growth failure in Costello syndrome: increased resting energy expenditure. J Pediatr. 2016;170:322–324. doi:10.1016/j.jpeds.2015.11.076
   PubMed Web of Science ®Google Scholar
• Aftab S, Dattani MT. Pathogenesis of growth failure in Rasopathies. Pediatr Endocrinol Rev. 2019;16(Suppl 2):447–458. doi:10.17458/per.vol16.2019.ad.pathogenesisrasopathies
   PubMedGoogle Scholar
• Leoni C, Giorgio V, Onesimo R, Kuczynska E, Zampino G. Impact of Costello syndrome on growth patterns. Am J Med Genet Part A. 2020;182(11):2797–2799. doi:10.1002/ajmg.a.61812
   PubMed Web of Science ®Google Scholar
• Mendoza MC, Er EE, Blenis J. The Ras-ERK and PI3K-mTOR pathways: cross-talk and compensation. Trends Biochem Sci. 2011;36(6):320–328. doi:10.1016/j.tibs.2011.03.006
   PubMed Web of Science ®Google Scholar
• Carpentieri G, Leoni C, Pietraforte D, et al. Hyperactive HRAS dysregulates energetic metabolism in fibroblasts from patients with Costello syndrome via enhanced production of reactive oxidizing species. Hum Mol Genet. 2021. doi:10.1093/hmg/ddab270
   Web of Science ®Google Scholar
• Gregersen N, Viljoen D. Costello syndrome with growth hormone deficiency and hypoglycemia: a new report and review of the endocrine associations. Am J Med Genet A. 2004;129A(2):171–175. doi:10.1002/ajmg.a.30189
   PubMed Web of Science ®Google Scholar
• Gripp KW, Lin AE. Costello syndrome: a Ras/mitogen activated protein kinase pathway syndrome (rasopathy) resulting from HRAS germline mutations. Genet Med. 2012;14(3):285–292. doi:10.1038/gim.0b013e31822dd91f
   PubMed Web of Science ®Google Scholar
• Fidan M, Chennappan S, Cirstea IC. Studying metabolic abnormalities in the Costello syndrome HRAS G12V mouse model: isolation of mouse embryonic fibroblasts and their in vitro adipocyte differentiation. Methods Mol Biol. 2021;2262:397–409. doi:10.1007/978-1-0716-1190-6_24
   PubMedGoogle Scholar
• Leoni C, Flex E. Costello syndrome: the challenge of hypoglycemia and failure to thrive. EBioMedicine. 2018;27:5–6. doi:10.1016/j.ebiom.2017.12.006
   PubMed Web of Science ®Google Scholar
• Oba D, Inoue S, Miyagawa-Tomita S, et al. Mice with an oncogenic HRAS mutation are resistant to high-fat diet-induced obesity and exhibit impaired hepatic energy homeostasis. EBioMedicine. 2018;27:138–150. doi:10.1016/j.ebiom.2017.11.029
   PubMed Web of Science ®Google Scholar
• Ugata K, Imamachi N, Hashimoto A, Saito Y. Anesthetic management in an adult patient with Costello syndrome: a case report. A&A Pract. 2019;13(2):41–43. doi:10.1213/xaa.0000000000000983
   PubMed Web of Science ®Google Scholar
• Dileone M, Zampino G, Profice P, et al. Dystonia in Costello syndrome. Parkinsonism Relat Disord. 2012;18(6):798–800. doi:10.1016/j.parkreldis.2012.03.015
   PubMed Web of Science ®Google Scholar
• Alfieri P, Piccini G, Caciolo C, et al. Differential effects of HRAS mutation on LTP-like activity induced by different protocols of repetitive transcranial magnetic stimulation. Am J Med Genet Part A. 2011;9(1):3445–3456. doi:10.1002/ajmg.a.36374
   Web of Science ®Google Scholar
• Romeo DM, Specchia A, Fasano A, et al. Treatment of dystonia using trihexyphenidyl in Costello syndrome. Brain Sci. 2020;10(7):450. doi:10.3390/brainsci10070450
   PubMed Web of Science ®Google Scholar
• Kawame H, Matsui M, Kurosawa K, et al. Further delineation of the behavioral and neurologic features in Costello syndrome. Am J Med Genet. 2003;118(1):8–14. doi:10.1002/ajmg.a.10236
   Web of Science ®Google Scholar
• Axelrad ME, Glidden R, Nicholson L, Gripp KW. Adaptive skills, cognitive, and behavioral characteristics of Costello syndrome. Am J Med Genet. 2004;128 A(4):396–400. doi:10.1002/ajmg.a.30140
   Web of Science ®Google Scholar
• Schreiber J, Grimbergen L-A, Overwater I, et al. Mechanisms underlying cognitive deficits in a mouse model for Costello syndrome are distinct from other RASopathy mouse models. Sci Rep. 2017;7(1):1256. doi:10.1038/s41598-017-01218-0
   PubMed Web of Science ®Google Scholar
• Kang M, Lee Y-S. The impact of RASopathy-associated mutations on CNS development in mice and humans. Mol Brain. 2019;12(1):96. doi:10.1186/s13041-019-0517-5
   PubMed Web of Science ®Google Scholar
• Gripp KW, Hopkins E, Doyle D, Dobyns WB. High incidence of progressive postnatal cerebellar enlargement in Costello syndrome: brain overgrowth associated with HRAS mutations as the likely cause of structural brain and spinal cord abnormalities. Am J Med Genet Part A. 2010;152(5):1161–1168. doi:10.1002/ajmg.a.33391
   Web of Science ®Google Scholar
• Calandrelli R, D’Apolito G, Marco P, Zampino G, Tartaglione T, Colosimo C. Costello syndrome: analysis of the posterior cranial fossa in children with posterior fossa crowding. Neuroradiol J. 2015;28(3):254–258. doi:10.1177/1971400915592549
   PubMedGoogle Scholar
• Lin AE, Alexander ME, Colan SD, et al. Clinical, pathological, and molecular analyses of cardiovascular abnormalities in Costello syndrome: a Ras/MAPK pathway syndrome. Am J Med Genet Part A. 2011;155(3):486–507. doi:10.1002/ajmg.a.33857
   Web of Science ®Google Scholar
• Gelb BD, Roberts AE, Tartaglia M. Cardiomyopathies in Noonan syndrome and the other RASopathies. Prog Pediatr Cardiol. 2015;39(1):13–19. doi:10.1016/j.ppedcard.2015.01.002
   PubMedGoogle Scholar
• Leoni C, Blandino R, Delogu AB, et al. Genotype-cardiac phenotype correlations in a large single-center cohort of patients affected by RASopathies: clinical implications and literature review. Am J Med Genet. 2021. doi:10.1002/ajmg.a.62529
   Web of Science ®Google Scholar
• Lioncino M, Monda E, Verrillo F, et al. Hypertrophic cardiomyopathy in rasopathies: diagnosis, clinical characteristics, prognostic implications, and management. Heart Fail Clin. 2022;18(1):19–29. doi:10.1016/j.hfc.2021.07.004
   PubMed Web of Science ®Google Scholar
• Kuniba H, Pooh RK, Sasaki K, et al. Prenatal diagnosis of Costello syndrome using 3D ultrasonography amniocentesis confirmation of the rare HRAS mutation G12D. Am J Med Genet A. 2009;149A(4):785–787. doi:10.1002/ajmg.a.32335
   PubMed Web of Science ®Google Scholar
• Mori M, Yamagata T, Mori Y, et al. Elastic fiber degeneration in Costello syndrome. Am J Med Genet. 1996;61(4):304–309. doi:10.1002/(SICI)1096-8628(19960202)61:4<304::AID-AJMG2>3.0.CO;2-U
   PubMed Web of Science ®Google Scholar
• Calcagni G, Gagliostro G, Limongelli G, et al. Atypical cardiac defects in patients with RASopathies: updated data on CARNET study. Birth Defects Res. 2020;112(10):725–731. doi:10.1002/bdr2.1670
   PubMed Web of Science ®Google Scholar
• Calcagni G, Limongelli G, D’Ambrosio A, et al. Data on cardiac defects, morbidity and mortality in patients affected by RASopathies. CARNET study results. Data Br. 2018;16:649–654. doi:10.1016/j.dib.2017.11.085
   PubMed Web of Science ®Google Scholar
• Calcagni G, Limongelli G, D’Ambrosio A, et al. Cardiac defects, morbidity and mortality in patients affected by RASopathies. CARNET study results. Int J Cardiol. 2017;245:92–98. doi:10.1016/j.ijcard.2017.07.068
   PubMed Web of Science ®Google Scholar
• Gomez-Ospina N, Kuo C, Ananth AL, et al. Respiratory system involvement in Costello syndrome. Am J Med Genet Part A. 2016;170(7):1849–1857. doi:10.1002/ajmg.a.37655
   PubMed Web of Science ®Google Scholar
• Vasta I, Scarano E, Rigante M, et al. Obstructive sleep apnea in Costello syndrome. Am J Hum Genet. 2006;221(3):212–221.
   Google Scholar
• Shikany AR, Baker L, Stabley DL, et al. Medically actionable comorbidities in adults with Costello syndrome. Am J Med Genet Part A. 2020;182(1):130–136. doi:10.1002/ajmg.a.61394
   PubMed Web of Science ®Google Scholar
• Alfieri P, Cesarini L, Zampino G, et al. Visual function in Noonan and LEOPARD syndrome. Neuropediatrics. 2008;39(6):335–340. doi:10.1055/s-0029-1216354
   PubMed Web of Science ®Google Scholar
• Pierpont ME, Richards M, Engel WK, Mendelsohn NJ, Summers CG. Retinal dystrophy in two boys with Costello syndrome due to the HRAS p.Gly13Cys mutation. Am J Med Genet A. 2017;173(5):1342–1347. doi:10.1002/ajmg.a.38110
   PubMed Web of Science ®Google Scholar
• Thakur A, Thakur V, Choudhary T, Mahajan R, Kulshrestha A, Gupta A. Anterior lenticular opacities in Costello syndrome. Am J Ophthalmol Case Rep. 2021;22:101036. doi:10.1016/j.ajoc.2021.101036
   PubMedGoogle Scholar
• Stevenson DA, Yang FC. The musculoskeletal phenotype of the RASopathies. Am J Med Genet C Semin Med Genet. 2011;157(2):90–103. doi:10.1002/ajmg.c.30296
   Web of Science ®Google Scholar
• Leoni C, Bisanti C, Viscogliosi G, et al. Bone tissue homeostasis and risk of fractures in Costello syndrome: a 4-year follow-up study. Am J Med Genet A. 2021. doi:10.1002/ajmg.a.62615
   Web of Science ®Google Scholar
• Siegel DH, Mann JA, Krol AL, Rauen KA. Dermatological phenotype in Costello syndrome: consequences of Ras dysregulation in development. Br J Dermatol. 2012;166(3):601–607. doi:10.1111/j.1365-2133.2011.10744.x
   PubMed Web of Science ®Google Scholar
• Marukian NV, Levinsohn JL, Craiglow BG, Milstone LM, Choate KA. Palmoplantar keratoderma in Costello syndrome responsive to acitretin. Pediatr Dermatol. 2017;34(2):160–162. doi:10.1111/pde.13057
   PubMed Web of Science ®Google Scholar
• Gripp KW. Tumor predisposition in Costello syndrome. Am J Med Genet C Semin Med Genet. 2005;137 C(1):72–77. doi:10.1002/ajmg.c.30065
   Web of Science ®Google Scholar
• Leoni C, Paradiso FV, Foschi N, et al. Prevalence of bladder cancer in Costello syndrome: new insights to drive clinical decision-making. Clin Genet. 2022;101(4):454–458. doi:10.1111/cge.14111
   PubMed Web of Science ®Google Scholar
• Menke J, Pauli S, Sigler M, et al. Uniparental trisomy of a mutated HRAS proto-oncogene in embryonal rhabdomyosarcoma of a patient with Costello syndrome. J Clin Oncol. 2015;33(13):e62–5. doi:10.1200/JCO.2013.49.6539
   PubMed Web of Science ®Google Scholar
• Johnson B, Goldberg-Strassler D, Gripp K, Thacker M, Leoni C, Stevenson D. Function and disability in children with Costello syndrome and Cardiofaciocutaneous syndrome. Am J Med Genet A. 2015;167A(1):40–44. doi:10.1002/ajmg.a.36828
   PubMed Web of Science ®Google Scholar
• Detweiler S, Thacker MM, Hopkins E, Conway L, Gripp KW. Orthopedic manifestations and implications for individuals with Costello syndrome. Am J Med Genet Part A. 2013;161(8):1940–1949. doi:10.1002/ajmg.a.36047
   Web of Science ®Google Scholar
• White SM, Graham JM, Kerr B, et al. The adult phenotype in Costello syndrome. Am J Med Genet. 2005;136 A(2):128–135. doi:10.1002/ajmg.a.30747
   Web of Science ®Google Scholar
• Reinker KA, Stevenson DA, Tsung A. Orthopaedic conditions in Ras/MAPK related disorders. J Pediatr Orthop. 2011;31(5):599–605. doi:10.1097/BPO.0b013e318220396e
   PubMed Web of Science ®Google Scholar
• Leoni C, Stevenson DA, Martini L, et al. Decreased bone mineral density in Costello syndrome. Mol Genet Metab. 2014;111(1):41–45. doi:10.1016/j.ymgme.2013.08.007
   PubMed Web of Science ®Google Scholar
• Leoni C, Viscogliosi G, Onesimo R, et al. Characterization of bone homeostasis in individuals affected by cardio-facio-cutaneous syndrome. Am J Med Genet A. 2022;188(2):414–421. doi:10.1002/ajmg.a.62588
   PubMed Web of Science ®Google Scholar
• Leoni C, Triumbari EKA, Vollono C, et al. Pain in individuals with RASopathies: prevalence and clinical characterization in a sample of 80 affected patients. Am J Med Genet Part A. 2019;179(6):940–947. doi:10.1002/ajmg.a.61111
   PubMed Web of Science ®Google Scholar
• Kiuru M, Urban J, Zhu G, et al. RAS pathway influences the number of melanocytic nevi in cardiofaciocutaneous and Costello syndromes. J Am Acad Dermatol. 2020;82(5):1091–1093. doi:10.1016/j.jaad.2020.01.038
   PubMed Web of Science ®Google Scholar
• Leoni C, Guerriero C, Onesimo R, et al. Melanocytic nevi in RASopathies: insights on dermatological diagnostic handles. J Eur Acad Dermatology Venereol. 2021;35(1):e83–e85. doi:10.1111/jdv.16824
   PubMed Web of Science ®Google Scholar
• Krab LC, Goorden SMI, Elgersma Y. Oncogenes on my mind: ERK and MTOR signaling in cognitive diseases. Trends Genet. 2008;24(10):498–510. doi:10.1016/j.tig.2008.07.005
   PubMed Web of Science ®Google Scholar
• Weeber EJ, Sweatt JD. Molecular neurobiology of human cognition. Neuron. 2002;33(6):845–848. doi:10.1016/s0896-6273(02)00634-7
   PubMed Web of Science ®Google Scholar
• Alfieri P, Piccini G, Caciolo C, et al. Behavioral profile in RASopathies. Am J Med Genet Part A. 2014;164(4):934–942. doi:10.1002/ajmg.a.36374
   Web of Science ®Google Scholar
• Bizaoui V, Gage J, Brar R, Rauen KA, Weiss LA. RASopathies are associated with a distinct personality profile HHS Public Access. Am J Med Genet B Neuropsychiatr Genet. 2018;177(4):434–446. doi:10.1002/ajmg.b.32632
   PubMed Web of Science ®Google Scholar
• Schwartz DD, Katzenstein JM, Highley EJ, et al. Age-related differences in prevalence of autism spectrum disorder symptoms in children and adolescents with Costello syndrome. Am J Med Genet Part A. 2017;173(5):1294–1300. doi:10.1002/ajmg.a.38174
   PubMed Web of Science ®Google Scholar
• Axelrad ME, Schwartz DD, Fehlis JE, et al. Longitudinal course of cognitive, adaptive, and behavioral characteristics in Costello syndrome. Am J Med Genet Part A. 2009;149(12):2666–2672. doi:10.1002/ajmg.a.33126
   Web of Science ®Google Scholar
• Perrino F, Licchelli S, Serra G, et al. Psychopathological features in Noonan syndrome. Eur J Paediatr Neurol. 2018;22(1):170–177. doi:10.1016/j.ejpn.2017.09.009
   PubMed Web of Science ®Google Scholar
• Axelrad ME, Schwartz DD, Katzenstein JM, Hopkins E, Gripp KW. Neurocognitive, adaptive, and behavioral functioning of individuals with Costello syndrome: a review. Am J Med Genet C Semin Med Genet. 2011;157(2):115–122. doi:10.1002/ajmg.c.30299
   Web of Science ®Google Scholar
• Della Marca G, Leoni C, Dittoni S, et al. Increased sleep spindle activity in patients with Costello syndrome (HRAS gene mutation). J Clin Neurophysiol. 2011;28(3):314–318. doi:10.1097/WNP.0b013e31821c3ad5
   PubMed Web of Science ®Google Scholar
• Leoni C, Gullo G, Resta N, et al. First evidence of a therapeutic effect of miransertib in a teenager with Proteus syndrome and ovarian carcinoma. Am J Med Genet A. 2019;179(7):1319–1324. doi:10.1002/ajmg.a.61160
   PubMed Web of Science ®Google Scholar
• De Luca A, Maiello MR, D’Alessio A, Pergameno M, Normanno N. The RAS/RAF/MEK/ERK and the PI3K/AKT signalling pathways: role in cancer pathogenesis and implications for therapeutic approaches. Expert Opin Ther Targets. 2012;16(Suppl 2):S17–27. doi:10.1517/14728222.2011.639361
   PubMed Web of Science ®Google Scholar
• Gross AM, Frone M, Gripp KW, et al. Advancing RAS/RASopathy therapies (ART): an NCI-sponsored intramural and extramural collaboration for the study of RASopathies. Am J Med Genet A. 2020;182(4):866–876. doi:10.1002/ajmg.a.61485
   PubMed Web of Science ®Google Scholar
• Kontaridis MI, Roberts AE, Schill L, et al. The seventh international RASopathies symposium: pathways to a cure-expanding knowledge, enhancing research, and therapeutic discovery. Am J Med Genet A. 2022. doi:10.1002/ajmg.a.62716
   PubMed Web of Science ®Google Scholar
• Markham A, Keam SJ. Selumetinib: first Approval. Drugs. 2020;80(9):931–937. doi:10.1007/S40265-020-01331-X
   PubMed Web of Science ®Google Scholar
• Gross AM, Wolters PL, Dombi E, et al. Selumetinib in children with inoperable plexiform Neurofibromas [published correction appears in N Engl J Med. 2020 Sep 24;383(13):1290]. N Engl J Med. 2020;382(15):1430–1442. doi:10.1056/NEJMoa1912735
   PubMed Web of Science ®Google Scholar
• Andelfinger G, Marquis C, Raboisson MJ, et al. Hypertrophic cardiomyopathy in Noonan syndrome treated by MEK-inhibition. J Am Coll Cardiol. 2019;73(17):2237–2239. doi:10.1016/j.jacc.2019.01.066
   PubMed Web of Science ®Google Scholar
• Jindal GA, Goyal Y, Burdine RD, Rauen KA, Shvartsman SY. RASopathies: unraveling mechanisms with animal models. Dis Models Mech. 2015. doi:10.1242/dmm.022442
   Web of Science ®Google Scholar
• Tidyman WE, Goodwin AF, Maeda Y, Klein OD, Rauen KA. MEK-inhibitor-mediated rescue of skeletal myopathy caused by activating Hras mutation in a Costello syndrome mouse model. Dis Model Mech. 2022;15(2). doi:10.1242/dmm.049166
   PubMed Web of Science ®Google Scholar
• Cox AD, Der CJ, Philips MR. Targeting RAS membrane association: back to the future for anti-RAS drug discovery? Clin Cancer Res. 2015;21(8):1819–1827. doi:10.1158/1078-0432.CCR-14-3214
   PubMed Web of Science ®Google Scholar
• Rosenberger G, Meien S, Kutsche K. Oncogenic HRAS mutations cause prolonged PI3K signaling in response to epidermal growth factor in fibroblasts of patients with Costello syndrome. Hum Mutat. 2009;30(3):352–362. doi:10.1002/humu.20855
   PubMed Web of Science ®Google Scholar
• Saini KS, Loi S, de Azambuja E, et al. Targeting the PI3K/AKT/mTOR and Raf/MEK/ERK pathways in the treatment of breast cancer. Cancer Treat Rev. 2013;39(8):935–946. doi:10.1016/j.ctrv.2013.03.009
   PubMed Web of Science ®Google Scholar
• Bergqvist C, Wolkenstein P. MEK inhibitors in RASopathies. Curr Opin Oncol. 2021;33(2):110–119. doi:10.1097/CCO.0000000000000711
   PubMed Web of Science ®Google Scholar
• Stevenson DA, Schill L, Schoyer L, et al. The fourth international symposium on genetic disorders of the Ras/MAPK pathway. Am J Med Genet Part A. 2016;170(8):1959–1966. doi:10.1002/ajmg.a.37723
   PubMed Web of Science ®Google Scholar
• Stoller JK. The challenge of rare diseases. Chest. 2018;153(6):1309–1314. doi:10.1016/j.chest.2017.12.018
   PubMed Web of Science ®Google Scholar
• Wilson BT, Hughes J. Joining the hidden revolution in rare diseases: working with family support groups. Arch Dis Child. 2020;105(2):107–108. doi:10.1136/archdischild-2019-317227
   PubMed Web of Science ®Google Scholar
• Germeni E, Vallini I, Bianchetti MG, Schulz PJ. Reconstructing normality following the diagnosis of a childhood chronic disease: does “rare” make a difference? Eur J Pediatr. 2018;177(4):489–495. doi:10.1007/s00431-017-3085-7
   PubMed Web of Science ®Google Scholar
• Delisle VC, Gumuchian ST, Rice DB, et al. Perceived benefits and factors that influence the ability to establish and maintain patient support groups in rare diseases: a scoping review. Patient. 2017;10(3):283–293. doi:10.1007/s40271-016-0213-9
   PubMedGoogle Scholar
• Anderson M, Elliott EJ, Zurynski YA. Australian families living with rare disease: experiences of diagnosis, health services use and needs for psychosocial support. Orphanet J Rare Dis. 2013;8(1):1. doi:10.1186/1750-1172-8-22
   PubMed Web of Science ®Google Scholar
• Baas M, Huisman S, van Heukelingen J, Koekkoek G, Laan HW, Hennekam RC. Building treasures for rare disorders. Eur J Med Genet. 2015;58(1):11–13. doi:10.1016/j.ejmg.2014.10.006
   PubMed Web of Science ®Google Scholar
• Bos JL. ras oncogenes in human cancer: a review. Cancer Res. 1989;49(17):4682–4689.
   PubMed Web of Science ®Google Scholar
• Aoki Y, Niihori T, Banjo T, et al. Gain-of-function mutations in RIT1 cause Noonan syndrome, a RAS/MAPK pathway syndrome. Am J Hum Genet. 2013;93(1):173–180. doi:10.1016/j.ajhg.2013.05.021
   PubMed Web of Science ®Google Scholar